At around the start of the 20th century, scientist Niels Ryberg Finsen developed a light-based treatment for lupus vulgaris, a form of TB that affects the face. Finsen’s work won him a Nobel ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

Clinical Images: Lupus vulgaris in a 58-year-old man ...

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 11.11%, which has investors questioning if this is right time ...

The new data show "robust benefit in lupus and DM,” William Blair analysts ... multiple sclerosis and pemphigus vulgaris (PV) across 50 sites in the U.S. and Europe. The biotech plans to share ...

Rarely, minocycline can cause hypersensitivity, drug-induced lupus erythematosus ... is approved for the treatment of acne vulgaris (and rosacea). Both nicotinamide and zinc oxide have anti ...

(NASDAQ:ARGX – Free Report) had its price target increased by Guggenheim from $775.00 to $1,100.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the ...

(NASDAQ:ARGX – Free Report) had its target price raised by HC Wainwright from $717.00 to $720.00 in a report published on ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Acne lesions are usually indistinguishable from acne vulgaris, both in appearance and ... findings that are also observed in systemic lupus erythematosus (SLE), a prototype autoimmune disease.